PittsburghV1, Main, Exploration, bibRecord, 004D68

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Identifieur interne : 004D68 ( Main/Exploration ); précédent : 004D67; suivant : 004D69

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Auteurs : J. Alexander Viehman [États-Unis] ; M. Hong Nguyen [États-Unis] ; YOHEI DOI [États-Unis]

Source :

Drugs : (Basel) [ 0012-6667 ] ; 2014.

RBID : Pascal:14-0226679

Descripteurs français

Pascal (Inist)
- Traitement, Dérivé du carbapénème, Résistance traitement, Acinetobacter baumannii, Infection, Article synthèse, Mécanisme action, Souche résistante carbapenem, Souche hautement résistante.

English descriptors

KwdEn :
- Acinetobacter baumannii, Carbapenem derivatives, Infection, Mechanism of action, Review, Treatment, Treatment resistance.

Abstract

Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmaco-kinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tige-cycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000631
to stream PascalFrancis, to step Curation: 004005
to stream PascalFrancis, to step Checkpoint: 000089
to stream Main, to step Merge: 005012
to stream Main, to step Curation: 004D68

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections</title>
<author><name sortKey="Viehman, J Alexander" sort="Viehman, J Alexander" uniqKey="Viehman J" first="J. Alexander" last="Viehman">J. Alexander Viehman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical Center, S319 Falk Medical Building, 3601 Fifth Avenue</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hong Nguyen, M" sort="Hong Nguyen, M" uniqKey="Hong Nguyen M" first="M." last="Hong Nguyen">M. Hong Nguyen</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antibiotic Management Program, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yohei Doi" sort="Yohei Doi" uniqKey="Yohei Doi" last="Yohei Doi">YOHEI DOI</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antibiotic Management Program, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>XDR Pathogen Laboratory, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical Center, S871 Scaife Hall, 3550 Terrace Street</s1>
<s2>Pittsburgh, PA 15261</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15261</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0226679</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0226679 INIST</idno>
<idno type="RBID">Pascal:14-0226679</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000631</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004005</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000089</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000089</idno>
<idno type="wicri:doubleKey">0012-6667:2014:Viehman J:treatment:options:for</idno>
<idno type="wicri:Area/Main/Merge">005012</idno>
<idno type="wicri:Area/Main/Curation">004D68</idno>
<idno type="wicri:Area/Main/Exploration">004D68</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections</title>
<author><name sortKey="Viehman, J Alexander" sort="Viehman, J Alexander" uniqKey="Viehman J" first="J. Alexander" last="Viehman">J. Alexander Viehman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical Center, S319 Falk Medical Building, 3601 Fifth Avenue</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hong Nguyen, M" sort="Hong Nguyen, M" uniqKey="Hong Nguyen M" first="M." last="Hong Nguyen">M. Hong Nguyen</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antibiotic Management Program, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yohei Doi" sort="Yohei Doi" uniqKey="Yohei Doi" last="Yohei Doi">YOHEI DOI</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antibiotic Management Program, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>XDR Pathogen Laboratory, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical Center, S871 Scaife Hall, 3550 Terrace Street</s1>
<s2>Pittsburgh, PA 15261</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15261</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acinetobacter baumannii</term>
<term>Carbapenem derivatives</term>
<term>Infection</term>
<term>Mechanism of action</term>
<term>Review</term>
<term>Treatment</term>
<term>Treatment resistance</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term>
<term>Dérivé du carbapénème</term>
<term>Résistance traitement</term>
<term>Acinetobacter baumannii</term>
<term>Infection</term>
<term>Article synthèse</term>
<term>Mécanisme action</term>
<term>Souche résistante carbapenem</term>
<term>Souche hautement résistante</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmaco-kinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tige-cycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Viehman, J Alexander" sort="Viehman, J Alexander" uniqKey="Viehman J" first="J. Alexander" last="Viehman">J. Alexander Viehman</name>
</noRegion>
<name sortKey="Hong Nguyen, M" sort="Hong Nguyen, M" uniqKey="Hong Nguyen M" first="M." last="Hong Nguyen">M. Hong Nguyen</name>
<name sortKey="Yohei Doi" sort="Yohei Doi" uniqKey="Yohei Doi" last="Yohei Doi">YOHEI DOI</name>
<name sortKey="Yohei Doi" sort="Yohei Doi" uniqKey="Yohei Doi" last="Yohei Doi">YOHEI DOI</name>
<name sortKey="Yohei Doi" sort="Yohei Doi" uniqKey="Yohei Doi" last="Yohei Doi">YOHEI DOI</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D68 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D68 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:14-0226679
   |texte=   Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri